Included were the ascorbate, fibronectin, hyaluronic acid, metalloproteinase inhibitors, EGF, FGF, NGF, insulin, and IGF-1 (corneal ulcer healing, Section 2.9 (Table 3)), the antiangiogenic agents (endostatin, PAI-1, PEDF, angiostatin, TSP-1, TSP-2, IFN-α (Section 3.2 (Table 4)), corticosteroids, NSAIDs, cyclosporine A, anti-VEGF drops (treatment of corneal neovascularization (Section 3.3.5 (Table 5)), and alpha-agonists, beta-blockers, carboanhydrase inhibitors, muscarinic agonists, Rho-kinase inhibitors, and prostaglandin analogues (glaucoma, Section 4.7, Table 6). This evidence concerns the gene COL18A1 and glaucoma.